Koga Clarissa C, Andrade Juan E, Ferruzzi Mario G, Lee Youngsoo
the Univ. of Illinois at Urbana-Champaign, 1304 W. Pennsylvania Ave, Urbana, IL, 61801, U.S.A.
the Purdue Univ, 745 Agriculture Mall Dr, West Lafayette, IN, 47906, U.S.A.
J Food Sci. 2016 Feb;81(2):C292-300. doi: 10.1111/1750-3841.13176. Epub 2015 Dec 17.
Trans-resveratrol has demonstrated the potential to provide both therapeutic and preventive activities against chronic diseases such as heart disease and cancer. The incorporation of trans-resveratrol into food products would allow for broader access of this bioactive compound to a larger population. However, this strategy is limited by instability of trans-resveratrol under environmental conditions and within the digestive system leading to isomerization of trans-resveratrol (bioactive form) to cis-resveratrol (bio-inactive form). Studies in the stabilization of trans-resveratrol into protein microparticles are presented. Trans-resveratrol was encapsulated using whey protein concentrate (WPC) or sodium caseinate (SC), with or without anhydrous milk fat (AMF). Binding of resveratrol and aromatic residues in protein was estimated utilizing the Stern-Volmer equation and the number of tryptophan residues. The stability of encapsulated resveratrol was evaluated after exposure to ultraviolet A (UVA) light and 3-stage in vitro digestion. After UVA light exposure, SC-based microcapsules maintained a higher trans:cis resveratrol ratio (0.63, P < 0.05) than WPC-based microcapsules (0.43) and unencapsulated resveratrol (0.49). In addition, encapsulation of resveratrol in both protein microparticles led to an increased digestive stability and bioaccessibility in comparison to unencapsulated resveratrol (47% and 23%, respectively, P < 0.05). SC-based microcapsules provided a higher digestive stability and bioaccessibility (86% and 81%; P < 0.05) compared to WPC-based microcapsules (71% and 68%). The addition of AMF to the microcapsules did not significantly change the in vitro digestion values. In conclusion, SC-based microencapsulation increased the stability of trans-resveratrol to UVA light exposure and simulated digestion conditions. This encapsulation-system-approach can be extended to other labile, bioactive polyphenols.
反式白藜芦醇已显示出对心脏病和癌症等慢性疾病具有治疗和预防作用的潜力。将反式白藜芦醇添加到食品中,可以让更多人接触到这种生物活性化合物。然而,这一策略受到反式白藜芦醇在环境条件及消化系统中稳定性的限制,会导致反式白藜芦醇(生物活性形式)异构化为顺式白藜芦醇(生物无活性形式)。本文介绍了将反式白藜芦醇稳定在蛋白质微粒中的研究。使用乳清蛋白浓缩物(WPC)或酪蛋白酸钠(SC),添加或不添加无水乳脂肪(AMF)来包封反式白藜芦醇。利用斯特恩 - 沃尔默方程和色氨酸残基数量估算白藜芦醇与蛋白质中芳香族残基的结合情况。在紫外线A(UVA)照射和3阶段体外消化后,评估包封白藜芦醇的稳定性。UVA照射后,基于SC的微胶囊保持的反式:顺式白藜芦醇比例(0.63,P < 0.05)高于基于WPC的微胶囊(0.43)和未包封的白藜芦醇(0.49)。此外,与未包封的白藜芦醇相比,两种蛋白质微粒中白藜芦醇的包封导致消化稳定性和生物可及性增加(分别为47%和23%,P < 0.05)。与基于WPC的微胶囊(71%和68%)相比,基于SC的微胶囊具有更高的消化稳定性和生物可及性(86%和81%;P < 0.05)。向微胶囊中添加AMF并未显著改变体外消化值。总之,基于SC的微胶囊化提高了反式白藜芦醇对UVA照射和模拟消化条件的稳定性。这种包封系统方法可扩展到其他不稳定的生物活性多酚。